more_reports

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks

  ()
Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly.
Tags: SilverBiotechnology / Pharmaceuticals

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff

  ()
Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains.
Tags: Special SituationsTechnologyOil & Gas - Exploration & ProductionSilverGoldCopperBiotechnology / PharmaceuticalsBase MetalsCritical Metals

Tech Firm Partners to Advance AI-Powered Support for MDs

  ()
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why.
Tags: Healthcare ServicesTechnology

Clean Tech Co.'s 'Forever Chemicals' Solution Featured in Industry Magazine

  ()
BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term.
Tags: Life Sciences Tools & DiagnosticsTechnologySpecial Situations

AI-Powered Healthcare Co. Gains Traction as US Expansion Accelerates

  ()
John Newell of John Newell & Associates shares why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.
Tags: Life Sciences Tools & Diagnostics

Data on 2 Drugs, Identified Via AI, Shared at Conference

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Water Treatment Firm Finds High-Performance Solution for $2.99B PFAS Market

  ()
Chemical Engineering magazine features BioLargo Inc. (OTCQX:BLGO) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) for its advancements in electrostatic PFAS treatment technology. Read why one expert likes this stock long-term.
Tags: Special SituationsTechnologyLife Sciences Tools & Diagnostics

AI Breakthroughs Drive New Momentum in Oncology Research

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences.
Tags: Biotechnology / Pharmaceuticals

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'

Research Report
  ()
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report.
Tags: Medical Devices

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive

  ()
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma.
Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Q3/25 Progress on Lead Programs Steady

Research Report
  ()
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers.
Tags: Biotechnology / Pharmaceuticals

Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results

  ()
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally.
Tags: Healthcare ServicesMedical Devices

US$12 Billion RNA Deal Triggers Sector Shakeup

  ()
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
Tags: Biotechnology / Pharmaceuticals

Preclinical Compounds Perform Better Than Existing Drugs

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss

  ()
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials

  ()
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.
Tags: Biotechnology / Pharmaceuticals

Biotech to Fast Track Phase 3 Depression Trial

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.
Tags: Biotechnology / Pharmaceuticals

2 Key Catalysts Ahead for Developer of Psych Drugs

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Co. Speeds Up Development of New Drug for Depression

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.
Tags: Biotechnology / Pharmaceuticals

Price Target on Psychiatric Drug Biotech Boosted 200%

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals